patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_457978 | REC_0017401 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 17 | 16.1 | 58 | female | 0 | 9 | 6.6 | 2 | alectinib 600 mg BID | 29.4 | false | MSS | 2026-03-15T05:36:02.161373+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_974284 | REC_0017402 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 28 | 12.1 | 78 | female | 1 | 11 | 5.5 | 2 | osimertinib 80 mg daily | 17.2 | false | MSS | 2026-03-15T05:36:02.161874+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_319021 | REC_0017403 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 27 | 5.4 | 76 | female | 2 | 65 | 3.7 | 7 | pembrolizumab 200 mg q3w | 7.4 | false | MSS | 2026-03-15T05:36:02.162331+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_572408 | REC_0017404 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 9.5 | 77 | female | 1 | 10 | 5.3 | 7 | alectinib 600 mg BID | 9.4 | false | MSS | 2026-03-15T05:36:02.162772+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_579678 | REC_0017405 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 14 | 10.8 | 60 | male | 0 | 15 | 6.3 | 6 | sotorasib 960 mg daily | 14.8 | true | MSS | 2026-03-15T05:36:02.163224+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_782627 | REC_0017406 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 13.2 | 70 | female | 1 | 9 | 5.1 | 2 | alectinib 600 mg BID | 15.9 | false | MSS | 2026-03-15T05:36:02.163654+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_130126 | REC_0017407 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 26 | 17.1 | 64 | female | 0 | 16 | 5 | 6 | pembrolizumab 200 mg q3w | 6 | false | MSI-H | 2026-03-15T05:36:02.164039+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_936402 | REC_0017408 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 12.2 | 68 | female | 1 | 17 | 4.6 | 6 | sotorasib 960 mg daily | 8.8 | false | MSI-H | 2026-03-15T05:36:02.164756+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_100385 | REC_0017409 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 16 | 68 | female | 1 | 21 | 5.8 | 6 | alectinib 600 mg BID | 11 | false | MSI-H | 2026-03-15T05:36:02.165210+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_993907 | REC_0017410 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 7.9 | 69 | female | 0 | 25 | 5.7 | 2 | sotorasib 960 mg daily | 23.5 | false | MSS | 2026-03-15T05:36:02.165633+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_962194 | REC_0017411 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 30 | 13.4 | 68 | female | 0 | 8 | 7.3 | 0 | entrectinib 600 mg daily | 41.2 | true | MSI-H | 2026-03-15T05:36:02.166039+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_855865 | REC_0017412 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 2.8 | 63 | female | 0 | 52 | 7.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 20.5 | true | MSS | 2026-03-15T05:36:02.166425+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_298633 | REC_0017413 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 16.4 | 60 | male | 0 | 9 | 5 | 4 | osimertinib 80 mg daily | 6.1 | false | MSI-H | 2026-03-15T05:36:02.166804+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_987047 | REC_0017414 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 18 | 5.6 | 65 | male | 0 | 12 | 4.7 | 2 | sotorasib 960 mg daily | 24.2 | true | MSS | 2026-03-15T05:36:02.167196+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_808744 | REC_0017415 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 8.9 | 57 | female | 0 | 17 | 6.8 | 5 | osimertinib 80 mg daily | 15.8 | false | MSS | 2026-03-15T05:36:02.167603+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_256621 | REC_0017416 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 21.4 | 59 | male | 1 | 17 | 8 | 3 | sotorasib 960 mg daily | 11.1 | false | MSS | 2026-03-15T05:36:02.167943+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_192686 | REC_0017417 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 18 | 16.3 | 65 | male | 1 | 8 | 5.9 | 5 | osimertinib 80 mg daily | 19.4 | true | MSI-H | 2026-03-15T05:36:02.168536+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_441166 | REC_0017418 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 28 | 8.2 | 63 | female | 0 | 21 | 5.3 | 1 | entrectinib 600 mg daily | 10.6 | false | MSS | 2026-03-15T05:36:02.171233+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_764421 | REC_0017419 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 12.7 | 62 | female | 1 | 12 | 4.5 | 7 | alectinib 600 mg BID | 9.6 | false | MSI-H | 2026-03-15T05:36:02.172019+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_320640 | REC_0017420 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 16 | 60 | female | 1 | 13 | 4.2 | 6 | alectinib 600 mg BID | 14.3 | false | MSS | 2026-03-15T05:36:02.172599+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_950657 | REC_0017421 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 17 | 15.7 | 71 | male | 2 | 27 | 4.5 | 6 | entrectinib 600 mg daily | 10.8 | true | MSI-H | 2026-03-15T05:36:02.173322+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_243476 | REC_0017422 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 13.2 | 76 | male | 2 | 20 | 3.3 | 5 | osimertinib 80 mg daily | 7.1 | false | MSS | 2026-03-15T05:36:02.173853+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_968305 | REC_0017423 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 23 | 5.4 | 60 | female | 1 | 18 | 6.5 | 4 | pembrolizumab 200 mg q3w | 15.6 | true | MSS | 2026-03-15T05:36:02.174223+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_309147 | REC_0017424 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 9.4 | 60 | male | 0 | 19 | 5 | 8 | entrectinib 600 mg daily | 14.4 | false | MSS | 2026-03-15T05:36:02.174534+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_416482 | REC_0017425 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 11.6 | 57 | male | 0 | 17 | 3.8 | 2 | osimertinib 80 mg daily | 17.2 | false | MSI-H | 2026-03-15T05:36:02.174839+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_846789 | REC_0017426 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 13.2 | 73 | female | 2 | 16 | 4.8 | 0 | osimertinib 80 mg daily | 19.4 | false | MSS | 2026-03-15T05:36:02.175158+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_347142 | REC_0017427 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 9.2 | 75 | female | 1 | 15 | 7 | 6 | sotorasib 960 mg daily | 12.7 | false | MSS | 2026-03-15T05:36:02.175500+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_469028 | REC_0017428 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 11.2 | 54 | male | 0 | 13 | 6.4 | 6 | sotorasib 960 mg daily | 12.5 | true | MSS | 2026-03-15T05:36:02.175836+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_396094 | REC_0017429 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 11 | 9.4 | 56 | male | 1 | 22 | 6.3 | 7 | entrectinib 600 mg daily | 10.5 | true | MSS | 2026-03-15T05:36:02.176230+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_316866 | REC_0017430 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 14.6 | 70 | male | 2 | 7 | 6.2 | 5 | osimertinib 80 mg daily | 10.9 | true | MSI-H | 2026-03-15T05:36:02.176582+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_429702 | REC_0017431 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 26 | 20.4 | 67 | male | 1 | 19 | 5.3 | 8 | pembrolizumab 200 mg q3w | 8 | false | MSS | 2026-03-15T05:36:02.176932+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_142834 | REC_0017432 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 18 | 67 | male | 1 | 21 | 7.9 | 1 | osimertinib 80 mg daily | 20.1 | false | MSS | 2026-03-15T05:36:02.177277+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_622142 | REC_0017433 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 6.6 | 72 | female | 2 | 57 | 7.7 | 7 | carboplatin + paclitaxel + pembrolizumab | 10.5 | true | MSS | 2026-03-15T05:36:02.177605+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_242271 | REC_0017434 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 23 | 7.3 | 59 | female | 0 | 20 | 4.1 | 1 | pembrolizumab 200 mg q3w | 17.3 | true | MSS | 2026-03-15T05:36:02.178448+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_663632 | REC_0017435 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 25 | 4.5 | 58 | female | 1 | 13 | 4.5 | 1 | pembrolizumab 200 mg q3w | 22 | false | MSS | 2026-03-15T05:36:02.178844+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_221293 | REC_0017436 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 31 | 10.6 | 51 | female | 0 | 19 | 5 | 4 | osimertinib 80 mg daily | 7 | true | MSS | 2026-03-15T05:36:02.179200+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_104346 | REC_0017437 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 7.8 | 90 | male | 1 | 14 | 7.9 | 3 | carboplatin + paclitaxel + pembrolizumab | 13.3 | false | MSS | 2026-03-15T05:36:02.179539+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_686020 | REC_0017438 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 35 | 14.9 | 73 | female | 2 | 20 | 6.7 | 2 | osimertinib 80 mg daily | 20.4 | true | MSI-H | 2026-03-15T05:36:02.179872+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_180615 | REC_0017439 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 10.4 | 81 | male | 2 | 10 | 5.4 | 5 | alectinib 600 mg BID | 4.8 | true | MSS | 2026-03-15T05:36:02.180290+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_459455 | REC_0017440 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 33 | 17.9 | 52 | female | 0 | 21 | 7.2 | 6 | sotorasib 960 mg daily | 9.9 | false | MSS | 2026-03-15T05:36:02.180641+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_988375 | REC_0017441 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 13.7 | 67 | female | 0 | 7 | 6.3 | 7 | entrectinib 600 mg daily | 13 | true | MSI-H | 2026-03-15T05:36:02.180964+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_517927 | REC_0017442 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 5.9 | 67 | male | 1 | 0 | 4.2 | 9 | carboplatin + paclitaxel + pembrolizumab | 16.6 | false | MSS | 2026-03-15T05:36:02.181312+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_309083 | REC_0017443 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 8 | 78 | female | 2 | 16 | 6.8 | 7 | alectinib 600 mg BID | 13 | false | MSS | 2026-03-15T05:36:02.181652+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_350064 | REC_0017444 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 16 | 15.8 | 70 | female | 1 | 15 | 4.5 | 1 | alectinib 600 mg BID | 5.9 | true | MSI-H | 2026-03-15T05:36:02.182052+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_245454 | REC_0017445 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 16.3 | 67 | female | 0 | 12 | 4.3 | 2 | osimertinib 80 mg daily | 19.6 | false | MSS | 2026-03-15T05:36:02.182435+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_849339 | REC_0017446 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 8.9 | 65 | female | 1 | 41 | 5.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 12.8 | false | MSS | 2026-03-15T05:36:02.182787+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_598897 | REC_0017447 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 15 | 11.2 | 72 | female | 2 | 12 | 2.6 | 6 | osimertinib 80 mg daily | 10.6 | false | MSI-H | 2026-03-15T05:36:02.183291+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_905400 | REC_0017448 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 31 | 8.8 | 66 | female | 1 | 28 | 5.4 | 2 | carboplatin + paclitaxel + pembrolizumab | 24.2 | true | MSS | 2026-03-15T05:36:02.183663+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_607495 | REC_0017449 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 7.8 | 77 | female | 3 | 25 | 6.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 17.4 | false | MSS | 2026-03-15T05:36:02.194611+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_557106 | REC_0017450 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 15.7 | 65 | female | 0 | 20 | 4.4 | 7 | osimertinib 80 mg daily | 16.1 | true | MSS | 2026-03-15T05:36:02.195641+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_510560 | REC_0017451 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 18 | 11.2 | 75 | male | 2 | 18 | 4 | 2 | osimertinib 80 mg daily | 28 | false | MSS | 2026-03-15T05:36:02.197408+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_861333 | REC_0017452 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 14.9 | 69 | female | 0 | 13 | 3.7 | 4 | osimertinib 80 mg daily | 10.3 | true | MSI-H | 2026-03-15T05:36:02.204830+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_259401 | REC_0017453 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 16.3 | 62 | male | 0 | 16 | 5.2 | 6 | sotorasib 960 mg daily | 8.6 | false | MSS | 2026-03-15T05:36:02.205645+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_421150 | REC_0017454 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 9.3 | 66 | female | 0 | 16 | 6.4 | 4 | osimertinib 80 mg daily | 22.9 | false | MSS | 2026-03-15T05:36:02.206504+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_704973 | REC_0017455 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 8.7 | 65 | male | 0 | 12 | 7.7 | 4 | entrectinib 600 mg daily | 10.3 | true | MSS | 2026-03-15T05:36:02.207498+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_375717 | REC_0017456 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 5 | 69 | male | 0 | 34 | 5.7 | 6 | carboplatin + paclitaxel + pembrolizumab | 12.6 | true | MSS | 2026-03-15T05:36:02.215713+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_502508 | REC_0017457 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 7.6 | 65 | female | 0 | 15 | 3.2 | 7 | osimertinib 80 mg daily | 6.3 | false | MSS | 2026-03-15T05:36:02.216845+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_296698 | REC_0017458 | Non-small cell lung cancer | Large cell carcinoma | III | None (PD-L1 high) | 22 | 9.5 | 79 | female | 1 | 3 | 5.9 | 0 | pembrolizumab 200 mg q3w | 47.2 | false | MSS | 2026-03-15T05:36:02.217900+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_809527 | REC_0017459 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 14.5 | 56 | female | 1 | 17 | 4.5 | 6 | pembrolizumab 200 mg q3w | 20 | true | MSI-H | 2026-03-15T05:36:02.218784+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_221270 | REC_0017460 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 6.2 | 64 | male | 1 | 25 | 6.9 | 6 | carboplatin + paclitaxel + pembrolizumab | 14.9 | false | MSS | 2026-03-15T05:36:02.219900+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_357511 | REC_0017461 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 12.7 | 67 | female | 0 | 18 | 5.1 | 4 | alectinib 600 mg BID | 10.8 | true | MSS | 2026-03-15T05:36:02.229004+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_805454 | REC_0017462 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 11.3 | 77 | female | 1 | 4 | 5.6 | 5 | alectinib 600 mg BID | 14 | false | MSS | 2026-03-15T05:36:02.229729+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_126548 | REC_0017463 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 15 | 64 | female | 0 | 16 | 5.2 | 5 | entrectinib 600 mg daily | 13.9 | false | MSS | 2026-03-15T05:36:02.230419+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_470077 | REC_0017464 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 34 | 8.1 | 69 | female | 0 | 64 | 5.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 17.2 | false | MSS | 2026-03-15T05:36:02.231140+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_198511 | REC_0017465 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 32 | 6.6 | 83 | female | 1 | 13 | 5.5 | 0 | alectinib 600 mg BID | 36.2 | true | MSS | 2026-03-15T05:36:02.237019+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_396906 | REC_0017466 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 11.5 | 69 | female | 0 | 9 | 6.3 | 1 | osimertinib 80 mg daily | 16.9 | true | MSS | 2026-03-15T05:36:02.238401+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_867930 | REC_0017467 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 11.3 | 68 | female | 1 | 10 | 5.6 | 1 | sotorasib 960 mg daily | 6.2 | true | MSI-H | 2026-03-15T05:36:02.239445+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_474526 | REC_0017468 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 16.2 | 77 | female | 3 | 2 | 4.8 | 2 | alectinib 600 mg BID | 21.9 | false | MSS | 2026-03-15T05:36:02.240630+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_708546 | REC_0017469 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 10.6 | 67 | female | 0 | 22 | 5.4 | 2 | osimertinib 80 mg daily | 23.4 | false | MSI-H | 2026-03-15T05:36:02.241940+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_434578 | REC_0017470 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 5.5 | 67 | female | 1 | 55 | 3 | 4 | carboplatin + paclitaxel + pembrolizumab | 18.4 | false | MSS | 2026-03-15T05:36:02.243114+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_863783 | REC_0017471 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 13.7 | 71 | male | 2 | 21 | 3.7 | 4 | alectinib 600 mg BID | 15.4 | false | MSI-H | 2026-03-15T05:36:02.243921+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_110307 | REC_0017472 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 12.1 | 70 | female | 2 | 7 | 3.9 | 2 | alectinib 600 mg BID | 17.7 | false | MSI-H | 2026-03-15T05:36:02.244865+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_916048 | REC_0017473 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 12 | 11.1 | 60 | male | 0 | 21 | 5.2 | 2 | osimertinib 80 mg daily | 16.3 | false | MSS | 2026-03-15T05:36:02.254238+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_487448 | REC_0017474 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 13.7 | 61 | female | 0 | 16 | 3.5 | 4 | pembrolizumab 200 mg q3w | 14.6 | false | MSI-H | 2026-03-15T05:36:02.255098+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_564858 | REC_0017475 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 14.8 | 76 | female | 2 | 11 | 6.7 | 7 | osimertinib 80 mg daily | 13.7 | false | MSS | 2026-03-15T05:36:02.256065+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_599155 | REC_0017476 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 15.3 | 63 | female | 0 | 18 | 5.4 | 5 | entrectinib 600 mg daily | 13.5 | false | MSI-H | 2026-03-15T05:36:02.261345+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_868162 | REC_0017477 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 9.5 | 80 | female | 2 | 17 | 4.8 | 1 | sotorasib 960 mg daily | 11.3 | false | MSS | 2026-03-15T05:36:02.267209+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_534287 | REC_0017478 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 17 | 7.9 | 60 | female | 0 | 25 | 4.2 | 7 | carboplatin + paclitaxel + pembrolizumab | 10.7 | true | MSS | 2026-03-15T05:36:02.268407+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_804055 | REC_0017479 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 17.7 | 57 | female | 1 | 11 | 3.7 | 8 | osimertinib 80 mg daily | 8.4 | false | MSS | 2026-03-15T05:36:02.269318+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_744689 | REC_0017480 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 17 | 17.4 | 64 | female | 0 | 16 | 4.8 | 2 | osimertinib 80 mg daily | 24.5 | true | MSS | 2026-03-15T05:36:02.270158+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_435477 | REC_0017481 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 27 | 7.8 | 61 | male | 1 | 9 | 6.6 | 0 | entrectinib 600 mg daily | 45.5 | true | MSS | 2026-03-15T05:36:02.275344+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_550134 | REC_0017482 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 13.3 | 83 | male | 2 | 14 | 5.8 | 6 | entrectinib 600 mg daily | 7.1 | false | MSI-H | 2026-03-15T05:36:02.276484+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_207591 | REC_0017483 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 11.4 | 61 | female | 1 | 7 | 6.5 | 2 | osimertinib 80 mg daily | 14.7 | true | MSS | 2026-03-15T05:36:02.277270+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_599519 | REC_0017484 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 11.5 | 62 | male | 1 | 14 | 6 | 1 | osimertinib 80 mg daily | 32.5 | false | MSS | 2026-03-15T05:36:02.278077+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_486320 | REC_0017485 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 12.2 | 89 | female | 1 | 8 | 5.8 | 11 | entrectinib 600 mg daily | 13.4 | false | MSI-H | 2026-03-15T05:36:02.278794+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_754208 | REC_0017486 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 28 | 16.8 | 65 | male | 1 | 8 | 5.1 | 1 | pembrolizumab 200 mg q3w | 24.8 | false | MSI-H | 2026-03-15T05:36:02.286000+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_657847 | REC_0017487 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 28 | 7.4 | 80 | male | 2 | 8 | 7.3 | 2 | pembrolizumab 200 mg q3w | 14.1 | false | MSS | 2026-03-15T05:36:02.286777+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_439663 | REC_0017488 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 16.1 | 72 | female | 1 | 8 | 4 | 5 | entrectinib 600 mg daily | 4.3 | true | MSS | 2026-03-15T05:36:02.292831+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_237783 | REC_0017489 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 31 | 4.9 | 75 | male | 3 | 24 | 6.3 | 5 | osimertinib 80 mg daily | 13.2 | false | MSS | 2026-03-15T05:36:02.293622+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_318682 | REC_0017490 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 33 | 15.1 | 64 | male | 0 | 2 | 6.5 | 5 | sotorasib 960 mg daily | 6.5 | true | MSI-H | 2026-03-15T05:36:02.297573+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_865118 | REC_0017491 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 26 | 12.8 | 49 | male | 0 | 17 | 3.9 | 2 | pembrolizumab 200 mg q3w | 9.8 | true | MSS | 2026-03-15T05:36:02.298466+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_687146 | REC_0017492 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 14.3 | 65 | male | 0 | 13 | 5.3 | 5 | sotorasib 960 mg daily | 14.5 | false | MSI-H | 2026-03-15T05:36:02.299314+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_118503 | REC_0017493 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 22 | 12.5 | 53 | male | 0 | 13 | 4.8 | 5 | pembrolizumab 200 mg q3w | 4.5 | false | MSS | 2026-03-15T05:36:02.301163+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_301986 | REC_0017494 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 9.1 | 69 | female | 1 | 7 | 6.8 | 6 | osimertinib 80 mg daily | 16.5 | false | MSS | 2026-03-15T05:36:02.302275+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_554639 | REC_0017495 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 6.7 | 61 | female | 1 | 25 | 5.2 | 1 | entrectinib 600 mg daily | 28.1 | false | MSS | 2026-03-15T05:36:02.303519+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_281657 | REC_0017496 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 9.7 | 76 | male | 2 | 11 | 6.3 | 8 | osimertinib 80 mg daily | 11.7 | false | MSS | 2026-03-15T05:36:02.304796+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_516356 | REC_0017497 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 14 | 68 | female | 0 | 20 | 7.1 | 9 | sotorasib 960 mg daily | 12.3 | false | MSS | 2026-03-15T05:36:02.307260+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_101918 | REC_0017498 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 8.7 | 80 | female | 2 | 15 | 5.2 | 7 | entrectinib 600 mg daily | 11.1 | true | MSS | 2026-03-15T05:36:02.308319+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_808885 | REC_0017499 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 31 | 13.1 | 46 | female | 0 | 17 | 3.4 | 4 | entrectinib 600 mg daily | 8.6 | false | MSI-H | 2026-03-15T05:36:02.309380+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_980566 | REC_0017500 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 31 | 17.6 | 55 | female | 0 | 14 | 4.5 | 1 | entrectinib 600 mg daily | 25.7 | false | MSI-H | 2026-03-15T05:36:02.310202+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.